share_log

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  08/06 16:05

Moomoo AI 已提取核心信息

Recursion Pharmaceuticals, Inc. reported on August 6, 2024, that it has successfully executed an option under its existing Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, originally signed on December 5, 2021. The option pertains to the first Neuroscience Phenomap that Recursion has generated. As a result of this exercise, Roche will pay Recursion an Acceptance Fee totaling $30 million. This financial event is part of the ongoing collaboration between the companies in the field of neuroscience.
Recursion Pharmaceuticals, Inc. reported on August 6, 2024, that it has successfully executed an option under its existing Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, originally signed on December 5, 2021. The option pertains to the first Neuroscience Phenomap that Recursion has generated. As a result of this exercise, Roche will pay Recursion an Acceptance Fee totaling $30 million. This financial event is part of the ongoing collaboration between the companies in the field of neuroscience.
Recursion Pharmaceuticals, Inc.于2024年8月6日报道,已成功根据其与Genentech, Inc.和F. Hoffmann-La Roche Ltd之间于2021年12月5日签署的现有合作及许可协议中的一个条款执行了一项选择权。此选择权与Recursion生成的第一个神经科学Phenomap相关。因此,罗氏将向Recursion支付总计3000万美元的认可费。这一财务事件是两家公司在神经科学领域持续合作的一部分。
Recursion Pharmaceuticals, Inc.于2024年8月6日报道,已成功根据其与Genentech, Inc.和F. Hoffmann-La Roche Ltd之间于2021年12月5日签署的现有合作及许可协议中的一个条款执行了一项选择权。此选择权与Recursion生成的第一个神经科学Phenomap相关。因此,罗氏将向Recursion支付总计3000万美元的认可费。这一财务事件是两家公司在神经科学领域持续合作的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息